Lilly's Retatrutide Delivers Big Weight Loss and Metabolic Benefits Across Obesity and Type 2 Diabetes Trials
At ADA 2026, Lilly deepened Triumph-1 data for retatrutide, a triple‑agonist GLP‑1/GIP/GLP‑2 program, showing up to 30% weight loss at 104 weeks with the 12 mg dose and meaningful knee osteoarthritis pain and sleep apnea improvements. In Type 2 diabetes, Transcend-T2D-1 reported substantial A1C reductions (around 1.9% at peak doses) with a high share of patients reaching target A1C levels (≤7%, ≤6.5%, and even <5.7%). Cardiometabolic benefits included sizable reductions in triglycerides, non-HDL cholesterol, systolic BP, and waist circumference. Safety signals included higher rates of urinary issues and dysesthesia, plus some arrhythmias and cardiovascular events in treated patients, though Lilly emphasized these events were relatively few. The data underscore Lilly’s strategy of offering multiple obesity medicines as it aims for broader regulatory approvals and patient options by decade’s end.